T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease

• Conditions: NAFLD; Heart Failure; Valvular Disease; Coronary Disease

• Registration Number: NCT04220450
• Lead Sponsor: Dr. Andreas Kammerlander

Brief Summary

On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver disease.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-01
• Study First Submitted: 2020-01-05
• Study First Submitted QC: 2020-01-06
• Last Update Submitted: 2020-01-06
• Study First Posted: 2020-01-07
• Last Update Posted: 2020-01-07
• Study Start: 2020-06-01
• Primary Completion: 2021-06-01
• Study Completion: 2021-06-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

• Referred for Cardiovascular Magnetic Resonance Imaging

Exclusion Criteria

• Non-compatible Devices

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation NAFLD and liver T1mapping	cross-sectional within one year	Correlation NAFLD risk score and liver T1-mapping (native and ECV9

Trial Locations

Locations (1)

Medical University of Vienna; 🇦🇹 Vienna, Austria